Alphamab IPO: Interims from Merck's Breast Cancer Trial Bodes Well for Alphamab and Junshi
Last night, Merck & Co Inc. (MRK US) announced that its Keytruda hits primary endpoint in Phase III (KEYNOTE-522) clinical trial in the...
681 Views
Versum Materials – Merck KGaA Not Going Away (Part II)
Since my initial report on Versum Materials (VSM US) last week, Versum Materials – Entegris Beaten to the Punch by Merck KGaA , I’ve dug deeper...
575 Views
Versum Materials – Entegris Beaten to the Punch by Merck KGaA
Merck KGaA (MRK GY), the German pharmaceutical and chemical company, gatecrashed the Entegris Inc (ENTG US)Â merger with Versum Materials (VSM...
929 Views
Celltrion Healthcare: Well, We Were Warned
Celltrion Healthcare (091990 KS) reported preliminary 2018 results that were dramatically short of expectations as the company cut shipments to...
720 Views
Biosimilar Battlefield: The Remsima/Inflectra Warning
2019 marks an inflection point for Korean biosimilar companies Celltrion Healthcare (091990 KS), Celltrion Inc (068270 KS), and Samsung Biologics...
830 Views